Therapeutic vaccines against HIV infection (Q38013505)

27 August 2017

Therapeutic vaccines against HIV infection (English)

1 reference

27 August 2017

1 reference

Agathe León

2

0 references

Felipe García

object named as

Felipe García

1

0 references

author name string

Josep M Gatell

3

1 reference

PubMed ID

22634436

27 August 2017

Montserrat Plana

4

1 reference

PubMed ID

22634436

27 August 2017

Teresa Gallart

5

1 reference

27 August 2017

1 May 2012

1 reference

Human Vaccines & Immunotherapeutics

27 August 2017

1 reference

27 August 2017

8

1 reference

27 August 2017

5

1 reference

27 August 2017

569-581

1 reference

Treatment as prevention--a double hat-trick

27 August 2017

1 reference

Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study

21 January 2018

1 reference

Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study

21 January 2018

1 reference

Newsmaker interview: Michel Sidibé. New HIV infections drop, but treatment demands rise. Interview by Jon Cohen

21 January 2018

1 reference

Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation

21 January 2018

1 reference

Evidence for the cure of HIV infection by CCR5Δ32/Δ32 stem cell transplantation

21 January 2018

1 reference

HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects.

21 January 2018

1 reference

Generation of HIV-1 resistant and functional macrophages from hematopoietic stem cell-derived induced pluripotent stem cells

21 January 2018

1 reference

Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys

21 January 2018

1 reference

The major genetic determinants of HIV-1 control affect HLA class I peptide presentation

21 January 2018

1 reference

AIDS. Boosting immunity to HIV--can the virus help?

21 January 2018

1 reference

Therapeutic vaccines for chronic infections

21 January 2018

1 reference

Immunopathogenesis and immunotherapy in AIDS virus infections

21 January 2018

1 reference

Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys

21 January 2018

1 reference

Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine

21 January 2018

1 reference

Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia

21 January 2018

1 reference

Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection

21 January 2018

1 reference

HIV preferentially infects HIV-specific CD4+ T cells

21 January 2018

1 reference

Comprehensive analysis of virus-specific T-cells provides clues for the failure of therapeutic immunization with ALVAC-HIV vaccine

21 January 2018

1 reference

Effects of in vivo CD8(+) T cell depletion on virus replication in rhesus macaques immunized with a live, attenuated simian immunodeficiency virus vaccine.

21 January 2018

1 reference

Resistance to replication of human immunodeficiency virus challenge in SCID-Hu mice engrafted with peripheral blood mononuclear cells of nonprogressors is mediated by CD8(+) T cells and associated with a proliferative response to p24 antigen

21 January 2018

1 reference

Progress in defining CD4 helper cell responses in chronic viral infections

21 January 2018

1 reference

Containment of simian immunodeficiency virus infection in vaccinated macaques: correlation with the magnitude of virus-specific pre- and postchallenge CD4+ and CD8+ T cell responses

21 January 2018

1 reference

Transfer of neutralizing IgG to macaques 6 h but not 24 h after SHIV infection confers sterilizing protection: implications for HIV-1 vaccine development.

21 January 2018

1 reference

Rapid evolution of the neutralizing antibody response to HIV type 1 infection

21 January 2018

1 reference

Selective escape from CD8+ T-cell responses represents a major driving force of human immunodeficiency virus type 1 (HIV-1) sequence diversity and reveals constraints on HIV-1 evolution

21 January 2018

1 reference

De novo generation of escape variant-specific CD8+ T-cell responses following cytotoxic T-lymphocyte escape in chronic human immunodeficiency virus type 1 infection

21 January 2018

1 reference

HIV-1 viral escape in infancy followed by emergence of a variant-specific CTL response.

21 January 2018

1 reference

The majority of currently circulating human immunodeficiency virus type 1 clade B viruses fail to prime cytotoxic T-lymphocyte responses against an otherwise immunodominant HLA-A2-restricted epitope: implications for vaccine design

21 January 2018

1 reference

Selection, transmission, and reversion of an antigen-processing cytotoxic T-lymphocyte escape mutation in human immunodeficiency virus type 1 infection

21 January 2018

1 reference

Immune selection for altered antigen processing leads to cytotoxic T lymphocyte escape in chronic HIV-1 infection

21 January 2018

1 reference

HIV evolution: CTL escape mutation and reversion after transmission

21 January 2018

1 reference

HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression

21 January 2018

1 reference

Impaired processing and presentation of cytotoxic-T-lymphocyte (CTL) epitopes are major escape mechanisms from CTL immune pressure in human immunodeficiency virus type 1 infection

21 January 2018

1 reference

21 January 2018

1 reference

Impacts of Avidity and Specificity on the Antiviral Efficiency of HIV-1-Specific CTL

21 January 2018

1 reference

High-level HIV-1 viremia suppresses viral antigen-specific CD4(+) T cell proliferation

21 January 2018

1 reference

Global dysfunction of CD4 T-lymphocyte cytokine expression in simian-human immunodeficiency virus/SIV-infected monkeys is prevented by vaccination

21 January 2018

1 reference

HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time

21 January 2018

1 reference

Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy

21 January 2018

1 reference

The challenge of viral reservoirs in HIV-1 infection

21 January 2018

1 reference

Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy.

21 January 2018

1 reference

21 January 2018

1 reference

Proliferation responses to HIVp24 during antiretroviral therapy do not reflect improved immune phenotype or function

21 January 2018

1 reference

Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy

21 January 2018

1 reference

Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression

21 January 2018

1 reference

Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per microL in Europe and North America: a pooled cohort observational study

21 January 2018

1 reference

Effect of early versus deferred antiretroviral therapy for HIV on survival

21 January 2018

1 reference

CD4+ count-guided interruption of antiretroviral treatment

21 January 2018

1 reference

Lymphoid tissue collagen deposition in HIV-infected patients correlates with the imbalance between matrix metalloproteinases and their inhibitors

21 January 2018

1 reference

Redistribution of FOXP3-positive regulatory T cells from lymphoid tissues to peripheral blood in HIV-infected patients.

21 January 2018

1 reference

Discontinuation of antiretroviral therapy commenced early during the course of human immunodeficiency virus type 1 infection, with or without adjunctive vaccination

21 January 2018

1 reference

Safety and immune responses to a DNA-based human immunodeficiency virus (HIV) type I env/rev vaccine in HIV-infected recipients: follow-up data

21 January 2018

1 reference

Two double-blinded, randomized, comparative trials of 4 human immunodeficiency virus type 1 (HIV-1) envelope vaccines in HIV-1-infected individuals across a spectrum of disease severity: AIDS Clinical Trials Groups 209 and 214.

21 January 2018

1 reference

A pilot phase II study of the safety and immunogenicity of HIV p17/p24:VLP (p24-VLP) in asymptomatic HIV seropositive subjects.

21 January 2018

1 reference

First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response

21 January 2018

1 reference

Loss of HIV-1-specific CD8+ T cell proliferation after acute HIV-1 infection and restoration by vaccine-induced HIV-1-specific CD4+ T cells

21 January 2018

1 reference

Cellular immune responses in asymptomatic human immunodeficiency virus type 1 (HIV-1) infection and effects of vaccination with recombinant envelope glycoprotein of HIV-1.

21 January 2018

1 reference

Efficacy testing of recombinant human immunodeficiency virus (HIV) gp160 as a therapeutic vaccine in early-stage HIV-1-infected volunteers. rgp160 Phase II Vaccine Investigators.

21 January 2018

1 reference

Phase II controlled trial of post-exposure immunization with recombinant gp160 versus antiretroviral therapy in asymptomatic HIV-1-infected adults. VaxSyn Protocol Team

21 January 2018

1 reference

Proliferative responses to human immunodeficiency virus type 1 (HIV-1) gp120 peptides in HIV-1-infected individuals immunized with HIV-1 rgp120 or rgp160 compared with nonimmunized and uninfected controls

21 January 2018

1 reference

A phase I evaluation of the safety and immunogenicity of vaccination with recombinant gp160 in patients with early human immunodeficiency virus infection. Military Medical Consortium for Applied Retroviral Research

21 January 2018

1 reference

A randomized, placebo-controlled study of the immunogenicity of human immunodeficiency virus (HIV) rgp160 vaccine in HIV-infected subjects with > or = 400/mm3 CD4 T lymphocytes (AIDS Clinical Trials Group Protocol 137).

21 January 2018

1 reference

Immunization with envelope MN rgp120 vaccine in human immunodeficiency virus-infected pregnant women

21 January 2018

1 reference

Reduced viral burden amongst high responder patients following HIV-1 p24 peptide-based therapeutic immunization

21 January 2018

1 reference

Therapeutic immunization with HIV-1 Tat reduces immune activation and loss of regulatory T-cells and improves immune function in subjects on HAART

21 January 2018

1 reference

Phase I therapeutic trial of the HIV-1 Tat protein and long term follow-up.

21 January 2018

1 reference

Vaccination with DNA containing tat coding sequences and unmethylated CpG motifs protects cynomolgus monkeys upon infection with simian/human immunodeficiency virus (SHIV89.6P).

21 January 2018

1 reference

Quantifying the uncertainty in forecasts of anthropogenic climate change

21 January 2018

1 reference

Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients.

21 January 2018

1 reference

Plasmid vaccination of stable HIV-positive subjects on antiviral treatment results in enhanced CD8 T-cell immunity and increased control of viral "blips".

21 January 2018

1 reference

Poxvirus vector-based HIV vaccines

21 January 2018

1 reference

MVA vaccination against smallpox: clinical tests with an attenuated live vaccinia virus strain (MVA) (author's transl)

21 January 2018

1 reference

The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses

21 January 2018

1 reference

Smallpox vaccination and its consequences: first experiences with the highly attenuated smallpox vaccine "MVA".

21 January 2018

1 reference

A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans

21 January 2018

1 reference

Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers

21 January 2018

1 reference

Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag c

21 January 2018

1 reference

Impact of therapeutic immunization on HIV-1 viremia after discontinuation of antiretroviral therapy initiated during acute infection

21 January 2018

1 reference

Safety and immunogenicity of ALVAC vCP1452 and recombinant gp160 in newly human immunodeficiency virus type 1-infected patients treated with prolonged highly active antiretroviral therapy

21 January 2018

1 reference

Therapeutic immunization with a human immunodeficiency virus (HIV) type 1-recombinant canarypox vaccine in chronically HIV-infected patients: The Vacciter Study (ANRS 094).

21 January 2018

1 reference

A randomized controlled trial of HIV therapeutic vaccination using ALVAC with or without Remune

21 January 2018

1 reference

Influence of IFNgamma co-expression on the safety and antiviral efficacy of recombinant fowlpox virus HIV therapeutic vaccines following interruption of antiretroviral therapy.

21 January 2018

1 reference

Biology of attenuated modified vaccinia virus Ankara recombinant vector in mice: virus fate and activation of B- and T-cell immune responses in comparison with the Western Reserve strain and advantages as a vaccine

21 January 2018

1 reference

Reduction of simian-human immunodeficiency virus 89.6P viremia in rhesus monkeys by recombinant modified vaccinia virus Ankara vaccination

21 January 2018

1 reference

Comparative efficacy of recombinant modified vaccinia virus Ankara expressing simian immunodeficiency virus (SIV) Gag-Pol and/or Env in macaques challenged with pathogenic SIV

21 January 2018

1 reference

Different patterns of immune responses but similar control of a simian-human immunodeficiency virus 89.6P mucosal challenge by modified vaccinia virus Ankara (MVA) and DNA/MVA vaccines.

21 January 2018

1 reference

Expansion and diversification of virus-specific T cells following immunization of human immunodeficiency virus type 1 (HIV-1)-infected individuals with a recombinant modified vaccinia virus Ankara/HIV-1 Gag vaccine.

21 January 2018

1 reference

Immunisation with recombinant modified vaccinia virus Ankara expressing HIV-1 gag in HIV-1-infected subjects stimulates broad functional CD4+ T cell responses

21 January 2018

1 reference

Safety and tolerability of recombinant modified vaccinia virus Ankara expressing an HIV-1 gag/multiepitope immunogen (MVA.HIVA) in HIV-1-infected persons receiving combination antiretroviral therapy

21 January 2018

1 reference

AIDS clinical trials group 5197: a placebo-controlled trial of immunization of HIV-1-infected persons with a replication-deficient adenovirus type 5 vaccine expressing the HIV-1 core protein

21 January 2018

1 reference

Factors associated with viral rebound in HIV-1-infected individuals enrolled in a therapeutic HIV-1 gag vaccine trial

21 January 2018

1 reference

Dendritic cells and the control of immunity

21 January 2018

1 reference

A phagosome-to-cytosol pathway for exogenous antigens presented on MHC class I molecules

21 January 2018

1 reference

A new foreign policy: MHC class I molecules monitor the outside world

21 January 2018

1 reference

Dendritic cells: from ontogenetic orphans to myelomonocytic descendants.

21 January 2018

1 reference

Vaccination against chlamydial genital tract infection after immunization with dendritic cells pulsed ex vivo with nonviable Chlamydiae

21 January 2018

1 reference

Therapeutic dendritic-cell vaccine for simian AIDS.

21 January 2018

1 reference

Potent immune response against HIV-1 and protection from virus challenge in hu-PBL-SCID mice immunized with inactivated virus-pulsed dendritic cells generated in the presence of IFN-alpha

21 January 2018

1 reference

Induction of protective immune responses against R5 human immunodeficiency virus type 1 (HIV-1) infection in hu-PBL-SCID mice by intrasplenic immunization with HIV-1-pulsed dendritic cells: possible involvement of a novel factor of human CD4(+) T-ce

21 January 2018

1 reference

A pilot clinical trial of HIV antigen-pulsed allogeneic and autologous dendritic cell therapy in HIV-infected patients.

21 January 2018

1 reference

Therapeutic dendritic-cell vaccine for chronic HIV-1 infection

21 January 2018

1 reference

Therapeutic immunization with human immunodeficiency virus type 1 (HIV-1) peptide-loaded dendritic cells is safe and induces immunogenicity in HIV-1-infected individuals

21 January 2018

1 reference

A randomized therapeutic vaccine trial of canarypox-HIV-pulsed dendritic cells vs. canarypox-HIV alone in HIV-1-infected patients on antiretroviral therapy

21 January 2018

1 reference

Immunologic activity and safety of autologous HIV RNA-electroporated dendritic cells in HIV-1 infected patients receiving antiretroviral therapy

21 January 2018

1 reference

A therapeutic dendritic cell-based vaccine for HIV-1 infection

21 January 2018

1 reference

Challenges in dendritic cells-based therapeutic vaccination in HIV-1 infection Workshop in dendritic cell-based vaccine clinical trials in HIV-1.

21 January 2018

1 reference

Evolution and transmission of stable CTL escape mutations in HIV infection

21 January 2018

1 reference

Therapeutic immunization with an inactivated HIV-1 Immunogen plus antiretrovirals versus antiretroviral therapy alone in asymptomatic HIV-infected subjects

21 January 2018

1 reference

Greater viral rebound and reduced time to resume antiretroviral therapy after therapeutic immunization with the ALVAC-HIV vaccine (vCP1452)

21 January 2018

1 reference

Therapeutic Immunization with Dendritic Cells Loaded with Heat‐Inactivated Autologous HIV‐1 in Patients with Chronic HIV‐1 Infection

21 January 2018

1 reference

First-Class Control of HIV-1

21 January 2018

1 reference

Immune control of HIV-1 after early treatment of acute infection

21 January 2018

1 reference

Persistence of HIV-1 Transcription in Peripheral-Blood Mononuclear Cells in Patients Receiving Potent Antiretroviral Therapy

21 January 2018

1 reference

CD8+, CD38+ Lymphocyte Percent

21 January 2018

1 reference

Therapeutic vaccination with MVA-HIV-1 nef elicits Nef-specific T-helper cell responses in chronically HIV-1 infected individuals

21 January 2018

1 reference

The therapeutic phase I trial of the recombinant native HIV-1 Tat protein

21 January 2018

1 reference

Serious Fatal and Nonfatal Non-AIDS-Defining Illnesses in Europe

21 January 2018

1 reference

Induction of novel CD8+ T-cell responses during chronic untreated HIV-1 infection by immunization with subdominant cytotoxic T-lymphocyte epitopes

21 January 2018

1 reference

Fatal and nonfatal AIDS and non-AIDS events in HIV-1-positive individuals with high CD4 cell counts according to viral load strata

21 January 2018

1 reference

Factors associated with collagen deposition in lymphoid tissue in long-term treated HIV-infected patients

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.4161/HV.19555

1 reference

27 August 2017

1 reference

PubMed ID

22634436